Skip to main content

Advertisement

SpringerLink
Log in

Prognostic Value of Renin–Angiotensin System Blockade in Non-muscle-invasive Bladder Cancer

  • Urologic Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

To determine whether the administration of renin–angiotensin system (RAS) inhibitors, such as angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs), affect disease outcome in non-muscle-invasive bladder cancer (NMIBC).

Methods

A total of 330 patients with initially diagnosed NMIBC were identified. We retrospectively investigated the clinical outcomes after transurethral resection of bladder tumor (TUR-BT) in patients who did or did not receive RAS inhibitors. The median follow-up period was 4.1 years.

Results

A total of 128 patients (38.8 %) experienced subsequent tumor recurrence, and stage progression was observed in 17 patients (5.2 %) during follow-up. Fifty-one patients (15.5 %) had received ACEI or ARB administration at transurethral resection. Multivariate analysis demonstrated that tumor multiplicity, absence of bacillus Calmette-Guérin instillation, and no administration of ACEI or ARB (P = 0.010, hazard ratio 2.26) were independent risk factors for subsequent tumor recurrence. The 5-year recurrence-free survival rate was 78.4 % in patients administered ACEIs or ARBs, and 53.3 % in their counterparts (P = 0.011).

Conclusions

The absence of RAS inhibitor administration was an independent risk factor for subsequent tumor recurrence in patients with initially diagnosed NMIBC. Our data support further investigation of the role of RAS inhibitors as a potential therapy to decrease tumor recurrence in NMIBC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.

    Article  PubMed  Google Scholar 

  2. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2008;54:303–14.

    Article  PubMed  Google Scholar 

  3. Nepple KG, Lightfoot AJ, Rosevear HM, O’Donnell MA, Lamm DL. Bacillus Calmette-Guérin with or without interferon alpha-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. J Urol. 2010;184:1915–9.

    Article  PubMed  Google Scholar 

  4. Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007;178:2314–30.

    Article  PubMed  Google Scholar 

  5. Lamm DL, Blumenstein BA, Crawford ED, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med. 1991;325:1205–9.

    Article  PubMed  CAS  Google Scholar 

  6. Sylvester RJ, van der Meijden A, Witjes JA, et al. High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology. 2005;66:90–107.

    Article  PubMed  Google Scholar 

  7. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol. 2000;163:1124–9.

    Article  PubMed  CAS  Google Scholar 

  8. Rivera E, Arrieta O, Guevara P, Duarte-Rojo A, Sotelo J. AT1 receptor is present in glioma cells; its blockage reduces the growth of rat glioma. Br J Cancer. 2001;85:1396–9.

    Article  PubMed  CAS  Google Scholar 

  9. Egami K, Murohara T, Shimada T, et al. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest. 2003;112:67–75.

    PubMed  CAS  Google Scholar 

  10. Juillerat-Jeanneret L, Celerier J, Chapuis Bernasconi C, et al. Renin and angiotensinogen expression and functions in growth and apoptosis of human glioblastoma. Br J Cancer. 2004;90:1059–68.

    Article  PubMed  CAS  Google Scholar 

  11. George AJ, Thomas WG, Hannan RD. The renin–angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer. 2010;10:745–59.

    Article  PubMed  CAS  Google Scholar 

  12. Miyajima A, Kosaka T, Asano T, Seta K, Kawai T, Hayakawa M. Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res. 2002;62:4176–9.

    PubMed  CAS  Google Scholar 

  13. Kosugi M, Miyajima A, Kikuchi E, Horiguchi Y, Murai M. Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer. Clin Cancer Res. 2006;12:2888–93.

    Article  PubMed  CAS  Google Scholar 

  14. Kosaka T, Miyajima A, Takayama E, et al. Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer. Prostate. 2007;67:41–9.

    Article  PubMed  CAS  Google Scholar 

  15. Tanaka N, Miyajima A, Kosaka T, et al. Cis-dichlorodiammineplatinum upregulates angiotensin II type 1 receptors through reactive oxygen species generation and enhances VEGF production in bladder cancer. Mol Cancer Ther. 2010;9:2982–92.

    Article  PubMed  CAS  Google Scholar 

  16. Shirotake S, Miyajima A, Kosaka T, et al. Angiotensin II type 1 receptor expression and microvessel density in human bladder cancer. Urology. 2011;77:1009e19–25.

    Google Scholar 

  17. Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD, Radwin HM. Bacillus Calmette-Guérin immunotherapy of superficial bladder cancer. J Urol. 1980;124:38–40.

    PubMed  CAS  Google Scholar 

  18. Malmstrom PU, Wijkstrom H, Lundholm C, Wester K, Busch C, Norlen BJ. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guérin in patients with superficial bladder carcinoma. Swedish–Norwegian Bladder Cancer Study Group. J Urol. 1999;161:1124–7.

    Article  PubMed  CAS  Google Scholar 

  19. Nieder AM, Brausi M, Lamm D, et al. Management of stage T1 tumors of the bladder. International Consensus Panel. Urology. 2005;66:108–25.

    Article  PubMed  Google Scholar 

  20. Lever AF, Hole DJ, Gillis CR, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet. 1998;352:179–84.

    Article  PubMed  CAS  Google Scholar 

  21. Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R, Jost E. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol. 2009;135:1429–35.

    Article  PubMed  CAS  Google Scholar 

  22. Nakai Y, Isayama H, Ijichi H, et al. Inhibition of renin–angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br J Cancer. 2010;103:1644–8.

    Article  PubMed  CAS  Google Scholar 

  23. Yoshiji H, Noguchi R, Toyohara M, et al. Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. J Hepatol. 2009;51:315–21.

    Article  PubMed  CAS  Google Scholar 

  24. Crew JP, O’Brien T, Bradburn M, et al. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res. 1997;57:5281–5.

    PubMed  CAS  Google Scholar 

  25. Santos L, Costa C, Pereira S, et al. Neovascularisation is a prognostic factor of early recurrence in T1/G2 urothelial bladder tumours. Ann Oncol. 2003;14:1419–24.

    Article  PubMed  CAS  Google Scholar 

  26. Szarvas T, Jager T, Totsch M, et al. Angiogenic switch of angiopietins-Tie2 system and its prognostic value in bladder cancer. Clin Cancer Res. 2008;14:8253–62.

    Article  PubMed  CAS  Google Scholar 

  27. Shirotake S, Miyajima A, Kosaka T, et al. Regulation of monocyte chemoattractant protein-1 through angiotensin II type 1 receptor in prostate cancer. Am J Pathol. 2012;180:1008–16.

    Article  PubMed  CAS  Google Scholar 

  28. Li X, Loberg R, Liao J, et al. A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. Cancer Res. 2009;69:1685–92.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

Supported in part by Grants-in-Aid for Scientific Research (24791671 to N.T. and 22591777 to A.M.) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan; and Grants-in-Aid from the Japanese Foundation for Multidisciplinary Treatment of Cancer.

Author information

Authors and Affiliations

  1. Department of Urology, Keio University School of Medicine, Tokyo, Japan

    Kazuyuki Yuge MD, Akira Miyajima MD, PhD, Nobuyuki Tanaka MD, Suguru Shirotake MD, Takeo Kosaka MD, PhD, Eiji Kikuchi MD, PhD & Mototsugu Oya MD, PhD

Authors
  1. Kazuyuki Yuge MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akira Miyajima MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nobuyuki Tanaka MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Suguru Shirotake MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takeo Kosaka MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Eiji Kikuchi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mototsugu Oya MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Akira Miyajima MD, PhD.

Additional information

Kazuyuki Yuge and Nobuyuki Tanaka contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yuge, K., Miyajima, A., Tanaka, N. et al. Prognostic Value of Renin–Angiotensin System Blockade in Non-muscle-invasive Bladder Cancer. Ann Surg Oncol 19, 3987–3993 (2012). https://doi.org/10.1245/s10434-012-2568-z

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-012-2568-z

Keywords

Search

Navigation